Welcome to our dedicated page for Cellebrite Di SEC filings (Ticker: CLBTW), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The CLBTW SEC filings page on Stock Titan surfaces U.S. regulatory documents connected to Cellebrite DI Ltd., the issuer whose shares trade on Nasdaq as CLBT and to which the CLBTW warrants are linked. As a foreign private issuer based in Israel, Cellebrite files an annual report on Form 20-F and furnishes current reports on Form 6-K under the Securities Exchange Act of 1934.
Recent Form 6-K filings referenced in the available data include press releases on second-quarter 2025 financial results and the appointment of a new chief executive officer, as well as the appointment of a chief financial officer and notice of the company’s annual general meeting of shareholders. These 6-Ks often incorporate GAAP financial statement tables and, in some cases, are expressly incorporated by reference into existing registration statements on Form S-8 and Form F-3. For investors tracking CLBTW, such filings help explain Cellebrite’s operating performance, governance changes and capital markets activity.
Cellebrite’s disclosures also discuss the use of non-GAAP financial measures such as non-GAAP gross profit, non-GAAP operating income, non-GAAP net income, Adjusted EBITDA and free cash flow, along with key performance indicators like annual recurring revenue and dollar-based net retention rate. The company explains why it believes these metrics provide additional insight beyond GAAP results, while also outlining their limitations.
On Stock Titan, users can review these SEC submissions in one place and use AI-powered tools to quickly interpret their contents. Filings related to CLBT and the associated warrants can be analyzed to understand how Cellebrite describes its digital investigation and intelligence business, risk factors, equity plans and financing activities. This page is a starting point for examining Form 20-F annual reports, Form 6-K current reports and other registered documents that define the regulatory and financial context for the CLBTW warrants.
Form 144 notice for Cellebrite DI Ltd. (CLBTW) reports a proposed sale of 12,878 common shares valued at $225,743.61 to be executed through Morgan Stanley Smith Barney LLC on 09/11/2025 on NASDAQ. The shares were acquired on 09/11/2025 by exercise of options under a registered plan and payment was for services rendered. The filing shows 244,469,106 shares outstanding, and indicates no securities sold by the filer in the past three months. The filer certifies they are not aware of undisclosed material adverse information.
Cellebrite DI Ltd. (CLBTW) Form 144 filing documents a proposed sale of 2,814 common shares by an insider through Morgan Stanley Smith Barney LLC on 09/08/2025 with an aggregate market value of $46,740.54. The filing shows the insider acquired 1,087 shares on 09/08/2025 by exercising stock options and 1,727 shares on 08/06/2025 via restricted stock units. The issuer has 244,469,106 shares outstanding per the form. The filer also reported a prior 10b5-1 sale of 2,814 shares on 08/20/2025 that generated gross proceeds of $43,954.68. The filer attests they are not aware of undisclosed material adverse information.
Cellebrite DI Ltd. (CLBTW) Form 144 notice shows an intended sale of 6,847 common shares through Goldman Sachs & Co. LLC on 09/02/2025, with an aggregate market value of $112,016.92 and 239,470,062 shares outstanding. The shares were acquired as restricted stock units: 1,021 shares vested on 08/31/2023 and 5,826 on 08/31/2024. The filer also reported a prior sale of 24,190 shares on 06/09/2025 for gross proceeds of $402,037.80. The notice includes the filer’s representation that they are not aware of any undisclosed material adverse information about the issuer.
Form 144 notice for CLBTW reports a proposed sale of 44,623 common shares with an aggregate market value of $722,768.43. The sale is noted as approximately on 08/27/2025 on NASDAQ. The filer documents acquisition details showing restricted stock grants on 02/14/2024 (22,003 shares), 05/14/2024 (5,497 shares) and 08/14/2025 (2,110 shares), plus a stock option exercise on 08/27/2025 for 15,013 shares paid in cash. The notice also lists two recent sales by the same person during the prior three months: 10,281 shares on 08/26/2025 for $164,651.09 and 37,965 shares on 08/25/2025 for $608,243.82. The filer attests there is no undisclosed material adverse information and follows Rule 144 disclosure requirements.
Form 144 notice for CLBTW (Cellebrite DI Ltd.) shows a proposed public sale of 10,281 common shares through Morgan Stanley Smith Barney (NASDAQ) with an aggregate market value of $164,651.09 and an approximate sale date of 08/26/2025. The filer reports acquiring 4,984 shares by stock option exercise on 08/26/2025 (paid in cash) and restricted stock grants of 3,387 shares on 08/14/2025 and 1,910 shares on 08/14/2024. The filing also discloses a prior sale on 08/25/2025 of 37,965 shares for gross proceeds of $608,243.82 by Zohar Tadmor. The notice includes the signers representation that no undisclosed material adverse information is known.
Cellebrite DI Ltd. (CLBTW) Form 144 notifies the market of a proposed sale of 37,965 common shares through Morgan Stanley Smith Barney LLC on 08/25/2025. The filing reports an aggregate market value of $608,243.80 for the shares and shows 244,469,106 shares outstanding for the issuer. Acquisition details in the form indicate the shares were obtained as restricted stock on 08/14/2024, 11/14/2024, 02/14/2025, and 05/14/2025 (amounts 3,587; 5,497; 5,497; 5,497 respectively) and via a stock option exercise on 08/25/2025 (17,887 shares, paid in cash). The filer reports no securities sold in the past three months. The notice includes the standard representation that the person signing does not possess undisclosed material adverse information about the issuer.
Cellebrite DI Ltd. (CLBTW) reported a proposed sale of 2,799 common shares through Morgan Stanley Smith Barney on NASDAQ with an aggregate market value of $44,532.09, and notes the securities were acquired as Restricted Stock Units on 08/20/2025. The filing shows recent dispositions by the same person: a sale of 2,874 shares on 08/21/2025 for $44,489.52 and a 10b5-1 plan sale of 12,150 shares on 05/23/2025 for $207,980.06. The filer certifies no undisclosed material adverse information and, where applicable, indicates reliance on a written 10b5-1 plan or trading instructions. This notice documents the planned transaction, the acquisition as RSUs, broker details, shares outstanding (244,469,106) and provides transparency about recent insider sales.
Cellebrite DI Ltd. Form 144 notice reports a proposed sale of 2,874 ordinary shares on 08/21/2025 through Morgan Stanley Smith Barney LLC on Nasdaq, with an aggregate market value of $44,489.52. The filer states there are 245,155,280 shares outstanding. The shares to be sold were partly acquired as 5,673 non-qualified performance stock units granted under an issuer S-8 plan on 08/20/2025, paid as employee compensation. The filing also discloses two prior sales by David Gee in May 2025 totaling 22,705 shares for gross proceeds of $381,590.05. The notice includes the standard certification that the seller does not possess undisclosed material adverse information.
Form 144 notice for CLBTW (Cellebrite DI Ltd.) discloses a proposed sale of 2,814 common shares, with an aggregate market value of $44,461.20, to be executed on 08/20/2025 on NASDAQ through Morgan Stanley Smith Barney LLC. The filing shows the shares were acquired by the reporting person from the issuer as follows: 1,087 shares via exercise of stock options on 08/20/2025 with cash payment, and 1,727 shares delivered as restricted stock units on 08/06/2025. The filing reports 244,469,106 shares outstanding for the class and indicates no securities sold in the past three months by the reporting person.
Form 144 notice for Cellebrite DI Ltd. (CLBTW) reports a proposed sale of 11,000 common shares through Morgan Stanley Smith Barney LLC on the NASDAQ, with an aggregate market value of $169,665.10 and approximately 239,470,062 shares outstanding. The filing shows the shares were originally acquired as restricted stock from the issuer on three dates: 5,826 shares on 08/31/2023, 3,768 shares on 07/18/2023, and 1,406 shares on 07/06/2024, and no sales by the filer in the past three months were reported.
The filer certifies they are not aware of undisclosed material adverse information about the issuer. The notice is procedural under Rule 144 to disclose an intended sale and does not include transaction proceeds, planned sale method beyond the broker, or additional contextual corporate details.